Skip to content

Treatment of loss of memory with Unani medicine Majoon-e-Baladur

Clinical validation of Unani pharmacopoeial formulation Majoon-e-Baladur in Nisyan (Amnesia) - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057437
Enrollment
110
Registered
2023-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R411- Anterograde amnesia

Interventions

Intervention1: Majun-e-Baladur: 5g (semisolid) to be taken orally with water after meals for 12weeks Control Intervention1: NIL: NIL

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of either sex in the age group 40-80 years 2. Individuals with subjective complaints of cognitive impairment 3. Subjects with MMSE score of 10-23 representing mild to moderate cognitive impairment

Exclusion criteria

Exclusion criteria: 1. Clinical presentation and/or history of any significant organic neurological diseases including space occupying lesions, stroke, head injury, seizure, and mental retardation 2. Subjects with impairment of speech, hearing and vision, which can impede the interview for MMSE and QOL assessment 3. Known cases of hypothyroidism or hyperthyroidism 4. Subjects with Vitamin B12 deficiency 5. Subjects on Psychotropic Drugs 6. Clinical presentation and/or history of a chronic disease that requires long-term treatment, e.g., DM, tuberculosis, HIV infection, syphilis, CVD, pulmonary disease, CKD, chronic liver disease, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could expose the patients to undue risk of a significant adverse event or interfere with assessment of safety or efficacy during the course of the trial 7. Pregnant and lactating females 8. H/o Addiction (alcohol, drugs)

Design outcomes

Primary

MeasureTime frame
The efficacy of the study drug in the treatment of mild to moderate Nisyan(Amnesia) will be assessed on the basis of improvement in the Mini Mental State Examination (MMSE) scoreTimepoint: At every 2 weeks for 12 weeks

Secondary

MeasureTime frame
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline & 12 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

naheedparveen802@gmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026